At close: December 20 at 4:00:01 PM EST
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 4 | 4 |
| Avg. Estimate | -0.91 | -0.7 | -4.77 | -2.86 |
| Low Estimate | -1.22 | -0.77 | -6.21 | -3.07 |
| High Estimate | -0.74 | -0.65 | -3.73 | -2.5 |
| Year Ago EPS | -- | -- | -- | -4.77 |
Revenue Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 2 | 3 | 4 |
| Avg. Estimate | 20.75k | 41.5k | 27.67k | 83.25k |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | 83k | 83k | 83k | 333k |
| Year Ago Sales | -- | -- | -- | 27.67k |
| Sales Growth (year/est) | -- | -- | -- | 200.87% |
Earnings History
| Currency in USD | 9/30/2024 |
|---|---|
| EPS Est. | -1.17 |
| EPS Actual | -24.19 |
| Difference | -23.02 |
| Surprise % | -1,967.52% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.91 | -0.7 | -4.77 | -2.86 |
| 7 Days Ago | -0.77 | -0.69 | -4.77 | -2.86 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | 1 | 1 |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | 1 | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| CAMP | -- | -- | -- | 40.07% |
| S&P 500 | 5.00% | 12.00% | 2.10% | 12.20% |
Upgrades & Downgrades
| Initiated | William Blair: Outperform | 11/5/2024 |
| Initiated | Leerink Partners: Outperform | 11/5/2024 |
| Initiated | JP Morgan: Overweight | 11/5/2024 |
| Initiated | Piper Sandler: Overweight | 11/5/2024 |
Related Tickers
UPB Upstream Bio, Inc.
16.21
-2.41%
KRRO Korro Bio, Inc.
43.67
+1.28%
BCAX Bicara Therapeutics Inc.
17.59
+5.96%
SER Serina Therapeutics, Inc.
6.00
+8.41%
CSBR Champions Oncology, Inc.
7.51
-0.60%
ZBIO Zenas BioPharma, Inc.
10.01
+2.56%
GYRE Gyre Therapeutics, Inc.
11.14
+4.50%
JUNS Jupiter Neurosciences, Inc.
9.73
-10.41%
SEPN Septerna, Inc.
24.28
+3.76%
PEPG PepGen Inc.
3.6300
-11.25%